En Es

Industry News

DIAsource Immunoassays Enters Agreement with ZenTech for RIA Products

By Labmedica International staff writers
31 Jul 2018

Image: DIAsource Immunoassays has entered into an agreement with ZenTech for its portfolio of radioimmunoassays (RIA) products (Photo courtesy of iStock).DIAsource Immunoassays (Brabant Wallon, Belgium), a BioVendor group company, has entered into a strategic agreement with ZenTech (Angleur, Belgium) under which ZenTech will transfer its portfolio of radioimmunoassays (RIA) products to DIAsource, securing their continued production and sales.

DIAsource ImmunoAssays is a diagnostics company specialized in the development, manufacturing, and sales and distribution of immunoassay tests and open instrumentation solutions for clinical diagnostics. It delivers manual RIA and ELISA kits and open automation solutions to the international markets, and has a portfolio of over 190 ELISA and 140 RIA assays. ZenTech specializes in the development, production and commercialization of solutions for clinical diagnostics of early life stage diseases and newborn screening. It has a broad portfolio of products in prenatal, neonatal and pediatric screening and offers complete and flexible solutions to set up the screening activity.

Both the companies have long standing collaborations for more than 15 years, with DIAsource already successfully managing a part of the commercialization of the ZenTech portfolio. The current transfer of RIA products from ZenTech to DIAsource is in line with their strategies. The portfolio to be transferred includes the complete line of special RIAs with thyroid markers and markers for fertility and salt balance. Effective July 24, 2018, DIAsource Immunoassays has assumed commercial ownership of ZenTech’s RIA product portfolio and will service clients from order to shipment, while ZenTech will remain the manufacturer during the transition period in which the production will be transferred to DIAsource. The transfer of production will be done in close collaboration and in phases to be concluded by September 30, 2019.

“Historically, ZenTech had a background and expertise in radioimmunoassays. However, when ZenTech acquired the Belgian company Gamma in 2011, it got access to new technologies and entered the market of newborn screening and early life stage diseases,” said Jean-Claude Havaux, Chairman of the Board, ZenTech. “Today's acquisition of the RIA products by ZenTech’s commercial partner DIAsource will guarantee RIA customers are offered long-term service and excellence in logistics worldwide. This transaction will give ZenTech the opportunity to focus on new innovative product lines and other technologies such as molecular diagnostics and mass spectrometry.”

“This acquisition is yet another step in our strategy to position DIAsource as a consolidator of manual specialty assays, after previous acquisitions of the Intertech RIA product line in 2012 and Viro-Immun ELISA and IFA product lines in 2017. DIAsource also acquired the RIA client businesses from distribution partners in France and Spain in 2015 and 2016. This fourth acquisition in the RIA space demonstrates our commitment to the long term future servicing and support of our large RIA customer base worldwide,” said Jef Vangenechten, CEO of DIAsource Immunoassays. “We experience that RIA remains important as the gold standard for assays that are not available on automated systems or for parameters that require a higher analytical accuracy, whereby manual assays offer benefits in terms of quality and flexibility versus price. DIAsource now has a unique position by combining the most complete offering of RIA specialty assays on the market with the ability to offer various RIA automation solutions. Furthermore our manual assays also allow customization for life science research and screening,” added Vangenechten.

E-mail Print
FaceBook Twitter Google+ Linked in


Develops, manufactures, and markets clinical diagnostic products that focus on endocrinology and infectious diseases
Gold member
More info

More articles about DIASOURCE

19 Sep 2017
DIAsource ImmunoAssays SA Acquires Viro-Immun Diagnostics
DIAsource ImmunoAssays SA, which develops, sells and distributes clinical diagnostics products, has acquired Viro-Immun Diagnostics GmbH, a developer and manufacturer of laboratory diagnostics for the medical diagnosis of infectious and autoimmune diseases.
Read More

Additional news

18 Oct 2018
Roche Launches Roche Healthcare Consulting
Roche (Basel, Switzerland) has launched Roche Healthcare Consulting, a specialized consulting service that aims to help leaders in laboratories, hospitals and other healthcare groups optimize their operational, clinical and financial performance.
Read More
18 Oct 2018
GE Healthcare and ESR Enter AI Partnership for ECR 2019
GE Healthcare (Chicago, IL, USA) and the European Society of Radiology (Vienna, Austria) will be partnering on artificial intelligence (AI) for the upcoming European Congress of Radiology (ECR) to be held in Vienna, Austria on February 27-March 3, 2019. The partnership will include joint sessions on AI and a dedicated space at GE Healthcare’s booth where visitors will be able to experience the AI transformation through interactive tools.
Read More
18 Oct 2018
AI-Based Approach Reduces False Positives in Mammography
A team of researchers from the University of Pittsburgh have developed an artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) that could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
Read More
18 Oct 2018
Global DR Detectors Market to Reach USD 2.7 Billion by 2026
The global digital radiography (DR) detectors market is projected to grow at a CAGR of 6.1% during 2018-2026 to reach a valuation of USD 2.71 billion by 2026, as an increase in the number of radiography tests performed each year, along with the introduction of new and advanced imaging equipment by key market players, drive the demand for DR detectors.
Read More
15 Oct 2018
AI Algorithm Uses Key Signatures to Predict Onset of AD
A team of researchers has designed an artificial intelligence (AI) algorithm that learns signatures from magnetic resonance imaging (MRI), genetics, and clinical data to accurately predict cognitive decline leading to Alzheimer’s disease. The algorithm can help predict whether an individual’s cognitive faculties are likely to deteriorate towards Alzheimer’s in the next five years.
Read More
15 Oct 2018
Breast Cancer Screening Machine Learning Software Receives CE Mark
A new deep learning-based breast cancer screening software has received the CE mark and will be launched within the UK’s National Health Service (NHS) and European healthcare systems. The software has been developed by Kheiron Medical Technologies, a start-up that combines novel deep learning methods, data science, and radiology expertise to enable diagnostics designed to detect cancers and improve patient outcomes.
Read More
15 Oct 2018
GE Healthcare to Implement First AI-Powered Hospital Command Centers
GE Healthcare is collaborating with hospital service providers in Europe and the US for implementing an artificial intelligence (AI)-powered command center to effectively and efficiently synchronize all elements of a patient's hospital experience. The AI-powered system will support caregivers to enhance patient safety, orchestrate seamless care delivery and get patients back home sooner.
Read More
11 Oct 2018
Scientists Use Machine Learning and MRI Scans to Predict Learning Difficulties
A team of scientists from the Medical Research Council (MRC) Cognition and Brain Sciences Unit at the University of Cambridge used machine learning - a type of artificial intelligence - with data from hundreds of children who struggle at school to identify clusters of learning difficulties, which did not match their previous diagnosis. According to the researchers, this reinforces the need for children to receive detailed assessments of their cognitive skills to identify the best type of support.
Read More
10 Oct 2018
Utilization of X-Ray Mammography Systems Expected to Increase
Over the last 20 years, hospitals and imaging centers in the developed economies have adopted X-ray mammography systems for the screening and diagnosis of breast cancer. This has resulted in a significant reduction in mortality and encouraged emerging countries to make investments in population-base, organized screening. These significant investments in mammography technology have paved the way for radiation safety, patient comfort and 3D imaging that enables precise tumor detection.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions